For in vitro diagnostic use. Others Elecsys PIVKA-II IVD Elecsys® PIVKA-II CPS_000497 09015043190 PIVKAII Elecsys E2G 300 V2 Elecsys PIVKA-II 07613336171981 Reagents, kits 300 tests cobas e 402/801 true 09014985190 PIVKAII Elecsys cobas e 100 V2 Elecsys PIVKA-II 07613336171967 Reagents, kits 100 tests cobas e 411/601/602 true 08333629190 PIVKAII Elecsys E2G 300 Elecsys PIVKA-II 07613336153895 Reagents, kits 300 tests cobas e 402/801 true 08333602190 PIVKAII Elecsys cobas e 100 Elecsys PIVKA-II 07613336153888 Reagents, kits 100 tests cobas e 411/601/602 true 09015043500 Elecsys PIVKA-II en 2 FF0000000584F10E FF000000049A180E 09015043190 2497 cobas e 801 9494 cobas e 402 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the quantitative measurement of protein induced by vitamin K absence or antagonist-II (PIVKA‑II) in human serum and plasma. The assay is used as an aid in the diagnosis of hepatocellular carcinoma (HCC). The results must be interpreted in conjunction with other methods in accordance with standard clinical management guidelines.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en 09014985500 Elecsys PIVKA-II en 1 FF000000049C010E FF0000000499BB0E 09014985190 618 cobas e 411 2325 cobas e 602 619 cobas e 601 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the quantitative measurement of protein induced by vitamin K absence or antagonist-II (PIVKA‑II) in human serum and plasma. The assay is used as an aid in the diagnosis of hepatocellular carcinoma (HCC). The results must be interpreted in conjunction with other methods in accordance with standard clinical management guidelines.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en 09014985500 Elecsys PIVKA-II en 2 FF0000000584DF0E FF000000049C010E 09014985190 618 cobas e 411 2325 cobas e 602 619 cobas e 601 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the quantitative measurement of protein induced by vitamin K absence or antagonist-II (PIVKA‑II) in human serum and plasma. The assay is used as an aid in the diagnosis of hepatocellular carcinoma (HCC). The results must be interpreted in conjunction with other methods in accordance with standard clinical management guidelines.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en 08333629500 Elecsys PIVKA-II en 2 FF000000037B740E FF0000000325CF0E 08333629190 2497 cobas e 801 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the quantitative measurement of protein induced by vitamin K absence or antagonist-II (PIVKA‑II) in human serum and plasma. The assay is used as an aid in the diagnosis of hepatocellular carcinoma (HCC). The results must be interpreted in conjunction with other methods in accordance with standard clinical management guidelines.The electrochemiluminescence immunoassay “ECLIA” is intended for use on the cobas e 801 immunoassay analyzer. en 08333629500 Elecsys PIVKA-II en 5 FF000000049FAA0E FF0000000456800E 08333629190 2497 cobas e 801 9494 cobas e 402 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the quantitative measurement of protein induced by vitamin K absence or antagonist-II (PIVKA‑II) in human serum and plasma. The assay is used as an aid in the diagnosis of hepatocellular carcinoma (HCC). The results must be interpreted in conjunction with other methods in accordance with standard clinical management guidelines.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en 08333629500 Elecsys PIVKA-II en 1 FF0000000325CF0E FF000000030F1F0E 08333629190 2497 cobas e 801 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the quantitative measurement of protein induced by vitamin K absence or antagonist-II (PIVKA‑II) in human serum and plasma. The assay is used as an aid in the diagnosis of hepatocellular carcinoma (HCC). The results must be interpreted in conjunction with other methods in accordance with standard clinical management guidelines.The electrochemiluminescence immunoassay “ECLIA” is intended for use on the cobas e 801 immunoassay analyzer. en ms_08333602190 Elecsys PIVKA-II en 3 FF000000045FF60E FF0000000325CE0E 08333602190 618 cobas e 411 2325 cobas e 602 619 cobas e 601 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the quantitative measurement of protein induced by vitamin K absence or antagonist-II (PIVKA‑II) in human serum and plasma. The assay is used as an aid in the diagnosis of hepatocellular carcinoma (HCC). The results must be interpreted in conjunction with other methods in accordance with standard clinical management guidelines.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en ms_08333602190 Elecsys PIVKA-II en 1 FF0000000325CE0E FF0000000311C40E 08333602190 618 cobas e 411 2325 cobas e 602 619 cobas e 601 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the quantitative measurement of protein induced by vitamin K absence or antagonist-II (PIVKA‑II) in human serum and plasma. The assay is used as an aid in the diagnosis of hepatocellular carcinoma (HCC). The results must be interpreted in conjunction with other methods in accordance with standard clinical management guidelines.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en